MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1073/pnas.2102975118

Медицинская библиотека · Proceedings of the National Academy of Sciences of the United States of America · 2021

Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.

Ambati Meenakshi, Apicella Ivana, Wang Shao-Bin, Narendran Siddharth, Leung Hannah, Pereira Felipe, Nagasaka Yosuke, Huang Peirong, Varshney Akhil, Baker Kirstie L, Marion Kenneth M, Shadmehr Mehrdad, Stains Cliff I, Werner Brian C, Sadda Srinivas R, Taylor Ethan W, Sutton S Scott, Magagnoli Joseph, Gelfand Bradley D

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The atrophic form of age-related macular degeneration (dry AMD) affects nearly 200 million people worldwide. There is no Food and Drug Administration (FDA)-approved therapy for this disease, which is the leading cause of irreversible blindness among people over 50 y of age. Vision loss in dry AMD results from degeneration of the retinal pigmented epithelium (RPE). RPE cell death is driven in part by accumulation of Alu RNAs, which are noncoding transcripts of a human retrotransposon. Alu RNA induces RPE degeneration by activating the NLRP3-ASC inflammasome. We report that fluoxetine, an FDA-approved drug for treating clinical depression, binds NLRP3 in silico, in vitro, and in vivo and inhibits activation of the NLRP3-ASC inflammasome and inflammatory cytokine release in RPE cells and macrophages, two critical cell types in dry AMD. We also demonstrate that fluoxetine, unlike several other antidepressant drugs, reduces Alu RNA-induced RPE degeneration in mice. Finally, by analyzing two health insurance databases comprising more than 100 million Americans, we report a reduced hazard of developing dry AMD among patients with depression who were treated with fluoxetine. Collectively, these studies identify fluoxetine as a potential drug-repurposing candidate for dry AMD.

Для цитирования: Ambati Meenakshi, Apicella Ivana, Wang Shao-Bin, Narendran Siddharth, Leung Hannah, Pereira Felipe, Nagasaka Yosuke, Huang Peirong, Varshney Akhil, Baker Kirstie L, Marion Kenneth M, Shadmehr Mehrdad, Stains Cliff I, Werner Brian C, Sadda Srinivas R, Taylor Ethan W, Sutton S Scott, Magagnoli Joseph, Gelfand Bradley D. Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.. Proceedings of the National Academy of Sciences of the United States of America. 2021. DOI: 10.1073/pnas.2102975118.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.